TY - JOUR T1 - Dr. Mazzantini replies JF - The Journal of Rheumatology JO - J Rheumatol SP - 1761 LP - 1761 DO - 10.3899/jrheum.120305 VL - 39 IS - 8 AU - MAURIZIO MAZZANTINI Y1 - 2012/08/01 UR - http://www.jrheum.org/content/39/8/1761.1.abstract N2 - To the Editor:When a patient is diagnosed with polymyalgia rheumatica (PMR), glucocorticoid (GC) therapy is mandatory, whatever the individual’s comorbidity. Strategies to reduce GC toxicity in high-risk patients include a lower starting GC dose than the usual 15–20 mg prednisolone, the association with methotrexate (MTX), the withdrawal of GC as soon as remission is achieved, a strict followup, and a pharmacological approach when appropriate (e.g., bisphosphonates to reduce fracture risk), along with general … E-mail: mmazzant{at}int.med.unipi.it ER -